A drug interaction may change total exposure more than a nominal dose suggests.
A phase I study in patients with lung cancer examined ceritinib with probe drugs. Midazolam exposure increased markedly under the tested coadministration conditions, supporting inhibition of CYP3A-mediated metabolism. A separate probe showed a different interaction magnitude.
The study used selected patients and a specific regimen. The group exposure ratio is not an individual impairment multiplier, and other clinical factors can affect sedation and clearance.
Include anticancer treatment in the medication timeline rather than reviewing benzodiazepines in isolation. Specify the actual substrate, route and treatment duration. The evidence supports a clinically relevant interaction concern, but cannot establish that the interaction caused a particular episode of altered awareness without patient-level timing and observations.
Source: PMC7946667, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Valerian Interaction Claims Need Separate Pharmacokinetic and Sedative Evidence.